Details
Title
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Author
Coombes, R. C. 1
; Howell, Sacha 2 ; Lord, Simon R. 3
; Kenny, Laura 1 ; Mansi, Janine 4 ; Mitri, Zahi 5
; Palmieri, Carlo 6
; Chap, Linnea I. 7 ; Richards, Paul 8 ; Gradishar, William 9
; Sardesai, Sagar 10 ; Melear, Jason 11 ; O’Shaughnessy, Joyce 11 ; Ward, Patrick 10
; Chalasani, Pavani 12 ; Arkenau, Tobias 13 ; Baird, Richard D. 14 ; Jeselsohn, Rinath 15
; Ali, Simak 1
; Clack, Glen 16 ; Bahl, Ashwani 16 ; McIntosh, Stuart 16 ; Krebs, Matthew G. 2
1 South Kensington, Imperial College, London, UK (GRID:grid.422248.a) (ISNI:0000 0001 2207 309X)
2 The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester, UK (GRID:grid.412917.8) (ISNI:0000 0004 0430 9259)
3 University of Oxford, Early Phase Clinical Trials Unit, Department of Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Guy’s and St Thomas’ NHS Foundation Trust, London, UK (GRID:grid.420545.2)
5 OHSU Knight Cancer Institute, Portland, USA (GRID:grid.516136.6)
6 University of Liverpool, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
7 University of California, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
8 Blue Ridge Cancer Center, Salem, USA (GRID:grid.19006.3e)
9 Northwestern University, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
10 US Oncology Research, OHC, Cincinnati, USA (GRID:grid.492834.0) (ISNI:0000 0004 0615 4027)
11 Baylor University Medical Center, Texas Oncology, Dallas, USA (GRID:grid.411588.1) (ISNI:0000 0001 2167 9807)
12 University of Arizona Cancer Center, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
13 Sarah Cannon Research Institute, London, UK (GRID:grid.477834.b) (ISNI:0000 0004 0459 7684)
14 Cancer Research UK Cambridge Centre, Cambridge, UK (GRID:grid.498239.d)
15 Dana-Farber Cancer Institute, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
16 Carrick Therapeutics, Dublin, Ireland (GRID:grid.422248.a)
; Howell, Sacha 2 ; Lord, Simon R. 3
; Kenny, Laura 1 ; Mansi, Janine 4 ; Mitri, Zahi 5
; Palmieri, Carlo 6
; Chap, Linnea I. 7 ; Richards, Paul 8 ; Gradishar, William 9
; Sardesai, Sagar 10 ; Melear, Jason 11 ; O’Shaughnessy, Joyce 11 ; Ward, Patrick 10
; Chalasani, Pavani 12 ; Arkenau, Tobias 13 ; Baird, Richard D. 14 ; Jeselsohn, Rinath 15
; Ali, Simak 1
; Clack, Glen 16 ; Bahl, Ashwani 16 ; McIntosh, Stuart 16 ; Krebs, Matthew G. 2
1 South Kensington, Imperial College, London, UK (GRID:grid.422248.a) (ISNI:0000 0001 2207 309X)
2 The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester, UK (GRID:grid.412917.8) (ISNI:0000 0004 0430 9259)
3 University of Oxford, Early Phase Clinical Trials Unit, Department of Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Guy’s and St Thomas’ NHS Foundation Trust, London, UK (GRID:grid.420545.2)
5 OHSU Knight Cancer Institute, Portland, USA (GRID:grid.516136.6)
6 University of Liverpool, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
7 University of California, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
8 Blue Ridge Cancer Center, Salem, USA (GRID:grid.19006.3e)
9 Northwestern University, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
10 US Oncology Research, OHC, Cincinnati, USA (GRID:grid.492834.0) (ISNI:0000 0004 0615 4027)
11 Baylor University Medical Center, Texas Oncology, Dallas, USA (GRID:grid.411588.1) (ISNI:0000 0001 2167 9807)
12 University of Arizona Cancer Center, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
13 Sarah Cannon Research Institute, London, UK (GRID:grid.477834.b) (ISNI:0000 0004 0459 7684)
14 Cancer Research UK Cambridge Centre, Cambridge, UK (GRID:grid.498239.d)
15 Dana-Farber Cancer Institute, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
16 Carrick Therapeutics, Dublin, Ireland (GRID:grid.422248.a)
Pages
4741
Publication year
2023
Publication date
2023
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2847160988
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.